Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.49 |
| ▸ | FLT4 | P35916 | 3/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 5/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | MST1R | Q04912 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30394605 | 0.91 | KDR (0.51) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL26099881 | 0.91 | KDR (0.51) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL26101851 | 0.90 | KDR (0.48) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL30394060 | 0.90 | EGFR (0.52) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL30393178 | 0.90 | KDR (0.48) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL26136652 | 0.90 | KDR (0.60) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL26135146 | 0.89 | AURKA (0.57) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL26135569 | 0.89 | AURKA (0.57) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL31137798 | 0.89 | AURKA (0.57) | KDRFLT4FLT1AURKAAURKB | |
| SCHEMBL30891768 | 0.89 | EPHX2 (0.51) | KDRFLT4FLT1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | claimed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | claimed |
| WO-2023075529-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2023-05-04 | — | — | WO | claimed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023075529-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | PDGFRA, KIT, PDGFRB | KDR 5/4885FLT4 19/4885FLT1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.